Imagenebio Inc (IMA)

$6.59 -0.13 (-1.93%)
Market Cap 75.14M
Revenue (ttm) 3.50M
Net Income (ttm) -49.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 742
Avg Vol 46,784
Day's Range N/A - N/A
Shares Out 11.18M
Stochastic %K 28%
Beta 0.43
Analysts Sell
Price Target $16.00

Company Profile

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 345 6265
Address:
12526 High Bluff Drive, Suite 345, San Diego, United States
BillionerOfKing
BillionerOfKing Feb. 26 at 9:17 PM
$IMA Current Stock Price: $6.84
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 2:29 PM
$IMA RSI: 42.31, MACD: -0.0674 Vol: 0.31, MA20: 7.00, MA50: 6.73 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
J7263
J7263 Feb. 18 at 6:27 PM
$IMA so glad I dumped this when I did. Illiquid diluted cash burning trash.
0 · Reply
RangeGhost
RangeGhost Feb. 10 at 2:10 PM
$IMA is a industrial manufacturing or asset company; performance tied to economic cycles.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 20 at 1:39 PM
$IMA Current Stock Price: $6.51
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 29 at 9:51 PM
Comparing trending tickers $IMA vs $STI: IMA has risen 10.52% to $6.41 with a trading volume of 351.8K shares, well above its average of 33.4K. STI, on the other hand, jumped 22.03% to $7.70 on a volume of 370.1K shares, although this is below its usual 1.0M shares traded. Both stocks are experiencing notable gains, but STI’s price surge is more pronounced even with a larger drop in relative trading volume compared to its average.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 29 at 9:39 PM
Comparing trending tickers $RAIN vs $IMA: RAIN is up 20.49% to $7.94 with a trading volume of 52.1K, which is above its average of 37.8K. Meanwhile, IMA has risen 10.52% to $6.41 on a much higher volume of 351.8K, significantly surpassing its usual 33.4K. Both stocks are experiencing substantial volume increases, but RAIN's percentage gain is notably higher despite a smaller increase in trading volume compared to IMA.
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Dec. 29 at 9:10 PM
$GLSI $IMA $PSLV A friend of mine followed this clown into a General store. He couldn’t buy anything specific. In fact The_Too_Gs sold him a pack of batteries. But they weren’t included. (Why do people spam us?)
0 · Reply
topstockalerts
topstockalerts Dec. 29 at 8:25 PM
$IMA Looking good! 👀
0 · Reply
thefalc0n
thefalc0n Dec. 29 at 8:03 PM
$IMA whats new?
0 · Reply
Latest News on IMA
ImageneBio to Participate in Leerink Global Healthcare Conference

Feb 26, 2026, 8:00 AM EST - 4 days ago

ImageneBio to Participate in Leerink Global Healthcare Conference

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Feb 10, 2026, 7:00 AM EST - 20 days ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

MLTX

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

Nov 12, 2025, 7:15 AM EST - 3 months ago

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

Nov 6, 2025, 8:30 AM EST - 4 months ago

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 4:15 PM EDT - 7 months ago

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

Jul 25, 2025, 11:00 AM EDT - 7 months ago

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

Jul 23, 2025, 9:00 AM EDT - 7 months ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

PSTX

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Jul 15, 2025, 4:15 PM EDT - 8 months ago

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Jul 11, 2025, 8:00 AM EDT - 8 months ago

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Dec 23, 2024, 8:37 AM EST - 1 year ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Ikena Oncology Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ikena Oncology Reports Third Quarter 2024 Financial Results

Ikena Oncology Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Reports Second Quarter 2024 Financial Results

UPDATE – Ikena Oncology Announces Strategic Update

May 28, 2024, 4:42 PM EDT - 1 year ago

UPDATE – Ikena Oncology Announces Strategic Update

Ikena Oncology Announces Strategic Update

May 28, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Announces Strategic Update

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

May 13, 2024, 4:45 PM EDT - 1 year ago

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 2 years ago

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Feb 21, 2024, 4:15 PM EST - 2 years ago

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Jan 18, 2024, 4:05 PM EST - 2 years ago

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 7:00 AM EST - 2 years ago

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Nov 7, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Ikena Oncology to Participate in September 2023 Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in September 2023 Investor Conferences

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena Oncology to Participate in Upcoming Investor Conferences

May 24, 2023, 8:00 AM EDT - 3 years ago

Ikena Oncology to Participate in Upcoming Investor Conferences

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

May 15, 2023, 7:50 AM EDT - 3 years ago

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Ikena Oncology Announces $40 Million Underwritten Offering

May 15, 2023, 7:45 AM EDT - 3 years ago

Ikena Oncology Announces $40 Million Underwritten Offering

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Apr 17, 2023, 9:00 AM EDT - 3 years ago

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 7:00 AM EDT - 3 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Mar 7, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Mar 6, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Feb 28, 2023, 8:00 AM EST - 3 years ago

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Ikena Oncology Appoints Owen Hughes as Board Chair

Dec 19, 2022, 4:30 PM EST - 3 years ago

Ikena Oncology Appoints Owen Hughes as Board Chair

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Nov 28, 2022, 8:00 AM EST - 3 years ago

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 7:30 AM EST - 3 years ago

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

Nov 10, 2022, 9:00 AM EST - 3 years ago

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:48 AM EST - 3 years ago

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:05 AM EST - 3 years ago

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Oct 26, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Oct 18, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 5, 2022, 8:05 AM EDT - 3 years ago

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Ikena Oncology to Participate in September 2022 Investor Conferences

Sep 6, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology to Participate in September 2022 Investor Conferences

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Aug 11, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

Jul 6, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

Jun 22, 2022, 7:00 AM EDT - 4 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

Ikena Oncology to Participate in Spring 2022 Investor Conferences

May 18, 2022, 7:00 AM EDT - 4 years ago

Ikena Oncology to Participate in Spring 2022 Investor Conferences

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 12, 2022, 7:00 AM EDT - 4 years ago

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

BillionerOfKing
BillionerOfKing Feb. 26 at 9:17 PM
$IMA Current Stock Price: $6.84
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 2:29 PM
$IMA RSI: 42.31, MACD: -0.0674 Vol: 0.31, MA20: 7.00, MA50: 6.73 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
J7263
J7263 Feb. 18 at 6:27 PM
$IMA so glad I dumped this when I did. Illiquid diluted cash burning trash.
0 · Reply
RangeGhost
RangeGhost Feb. 10 at 2:10 PM
$IMA is a industrial manufacturing or asset company; performance tied to economic cycles.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 20 at 1:39 PM
$IMA Current Stock Price: $6.51
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 29 at 9:51 PM
Comparing trending tickers $IMA vs $STI: IMA has risen 10.52% to $6.41 with a trading volume of 351.8K shares, well above its average of 33.4K. STI, on the other hand, jumped 22.03% to $7.70 on a volume of 370.1K shares, although this is below its usual 1.0M shares traded. Both stocks are experiencing notable gains, but STI’s price surge is more pronounced even with a larger drop in relative trading volume compared to its average.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 29 at 9:39 PM
Comparing trending tickers $RAIN vs $IMA: RAIN is up 20.49% to $7.94 with a trading volume of 52.1K, which is above its average of 37.8K. Meanwhile, IMA has risen 10.52% to $6.41 on a much higher volume of 351.8K, significantly surpassing its usual 33.4K. Both stocks are experiencing substantial volume increases, but RAIN's percentage gain is notably higher despite a smaller increase in trading volume compared to IMA.
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Dec. 29 at 9:10 PM
$GLSI $IMA $PSLV A friend of mine followed this clown into a General store. He couldn’t buy anything specific. In fact The_Too_Gs sold him a pack of batteries. But they weren’t included. (Why do people spam us?)
0 · Reply
topstockalerts
topstockalerts Dec. 29 at 8:25 PM
$IMA Looking good! 👀
0 · Reply
thefalc0n
thefalc0n Dec. 29 at 8:03 PM
$IMA whats new?
0 · Reply
SanJose2
SanJose2 Dec. 29 at 8:00 PM
$IMA finally, 45 % institutional ownership.
0 · Reply
echo_fable
echo_fable Dec. 29 at 7:56 PM
$IMA
0 · Reply
echo_fable
echo_fable Dec. 29 at 7:25 PM
$IMA 42 watchers only
1 · Reply
echo_fable
echo_fable Dec. 29 at 7:25 PM
$IMA 6-7$ next
1 · Reply
echo_fable
echo_fable Dec. 29 at 7:25 PM
$IMA
0 · Reply
echo_fable
echo_fable Dec. 29 at 7:25 PM
$IMA 1
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 9:06 PM
$IMA
0 · Reply
THSSKS
THSSKS Dec. 9 at 2:58 PM
$IMA this is going to end up with all the other cash rich bio turds. Wouldn’t touch this one again until data a year away. Everyone has a treatment for atopic dermatitis too, nothing fancy here. Alopecia treatment is trash.
2 · Reply
WallStArb
WallStArb Nov. 25 at 5:19 PM
$IMA exited some more 7.35 - 7.41 - derisking until I confirm the Wedbush reasoning why they expect it to be worth $2 or $25M market cap
0 · Reply
WallStArb
WallStArb Nov. 25 at 2:59 PM
$IMA sold a few I picked up yesterday @ 6.91 for 7.20 - 7.25 will wait to rebuy
1 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 2:04 PM
Wedbush has adjusted their stance on ImageneBio ( $IMA ), setting the rating to Underperform with a target price of 2.
1 · Reply
J7263
J7263 Nov. 25 at 4:43 AM
$IMA no catalysts until q4 2026. Don't forget about the opportunity cost 😬.
1 · Reply